Hypersensitivity Reactions to Biologicals: from Bench to Bedside

Abstract

Purpose of Review Biologic agents are new treatment options for chronic inflammatory diseases and cancers. As a result of their unique mechanism of action, they are more effective and less toxic treatment option and their clinical usage is increasing. While they are more commonly used, various adverse effects have been observed including lifethreatening ones, including anaphylaxis. The aim of this review is to distinguish the anaphylaxis from other hypersensitivity reactions (HSR) and provide a management algorithm for the anaphylactic reactions induced by biological agents. Recent Findings Many case reports and series have been published regarding anaphylaxis and other hypersensitivity reactions (concerning cytokine release syndrome, acute infusion-related reactions) due to biologic agents. Although acute treatment of HSR varies according to the clinical presentation, desensitization with the drug is the major management option for subsequent administrations in the case of anaphylactic reactions. Summary Anaphylaxis and other immediate onset hypersensitivity reactions are occasionally difficult to differentiate from each other, and mixed-type reactions may be observed. Immediate management of anaphylaxis includes discontinuation of infusion, immediate administration of adrenaline, antihistamines, corticosteroids, and other treatment options depending on the symptoms. After 30-120 min of the reaction, a blood sample for serum tryptase levels should be obtained and after 4-6 weeks skin testing with the culprit drug should be performed for decision of long-term management via either graded challenge or desensitization.

Safety profile of anifrolumab in patients with active SLE: an integrated analysis of phase II and III trials

“… 16 Protein-based infusions also pose risks of hypersensitivity reactions and other infusion-related reactions, independent of the drug’s mechanism of action. 17 …”

Atezolizumab-induced anaphylactic shock in a patient with hepatocellular carcinoma undergoing immunotherapy: A case report

“…Immediate-onset HSRs include IgE-mediated hypersensitivity reactions, acute infusion–related reactions, and cytokine release syndrome. However, these reactions may be clinically indistinguishable from each other, and patients may show mixed-type reactions[ 12 , 13 ]. An increase of serum tryptase indicates mast cell/basophil degranulation and suggests the possibility of an IgE-mediated reaction.…”

“…If the patient shows no response to adrenaline within 5-10 min, epinephrine administration should be repeated. Second-line and third-line treatments include adequate positioning, oxygen, nebulized adrenaline, nebulized beta-2-agonist, intravenous normal saline, corticosteroid, and antihistamine administration depending on the clinical presentations of the patient[ 13 , 15 ]. The target oxygen saturation is > 94% to 96%.…”

Reacciones de hipersensibilidad a quimioterapéuticos y biológicos

“…Actualmente se encuentran aprobados más de 150 agentes biológicos, y este número cada vez es más amplio [9]. Como resultado, se ha observado un incremento de sus efectos adversos, tanto inmunológicos como no inmunológicos [15]. Para comprender mejor estas reacciones adversas, es importante tener en cuenta algunas diferencias clave entre los fármacos y los agentes biológicos.…”